Import from '@/components/mdx'

Crestor vs Repatha for Women: A Head-to-Head Comparison Across Life Stages

What These Two Drugs Actually Do (and Why Women Are Different)

Rosuvastatin and evolocumab both lower LDL cholesterol, but they work through entirely different mechanisms, occupy different places in the treatment pathway, and carry different risk profiles that matter specifically for women.

Rosuvastatin blocks HMG-CoA reductase, the enzyme your liver uses to make cholesterol. This raises LDL receptor expression and clears more LDL from your blood. Evolocumab neutralizes PCSK9, a protein that normally destroys LDL receptors. By blocking PCSK9, your liver keeps more receptors on its surface and pulls far more LDL from circulation.

Women metabolize rosuvastatin differently than men. Data from the JUPITER trial showed that women assigned to rosuvastatin 20 mg achieved a median LDL reduction of approximately 50%, with women making up 38% of the 17,802-participant cohort. Women in JUPITER reached the primary cardiovascular endpoint reduction at a lower absolute event rate than men, reflecting the different baseline cardiovascular risk profile women carry in the pre-menopausal and early post-menopausal years.

Sex-specific pharmacokinetics for rosuvastatin are real. Women tend to show roughly 50% higher plasma rosuvastatin concentrations than men at equivalent doses, likely driven by differences in body weight, hepatic uptake, and hormonal influences on CYP2C9 and OATP transporters. This means a woman may achieve target LDL on a lower milligram dose than her male counterpart, and dose-related myopathy risk needs to be weighed accordingly.

For evolocumab, the FOURIER trial enrolled 27,564 patients with established ASCVD on background statin therapy and found that evolocumab 140 mg every two weeks or 420 mg monthly reduced LDL by 59% from a median baseline of 92 mg/dL. Women represented only about 24.5% of FOURIER participants. The primary endpoint reduction (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was a statistically significant 15% relative risk reduction, and the directional benefit in women was consistent, though the subgroup was underpowered to confirm independently significant effects in women alone.

This evidence gap matters. For a drug that costs over $500 per month and requires a biweekly injection, knowing that the female-specific evidence is extrapolated rather than directly replicated is information every woman deserves before she decides.

How Cardiovascular Risk Shifts Across a Woman's Life

Reproductive Years (Ages 18 to 40)

Before menopause, estrogen provides relative cardiovascular protection by raising HDL, improving endothelial function, and reducing LDL oxidation. High LDL in your twenties or thirties usually signals a genetic condition, dietary pattern, or a secondary cause. PCOS is the most common hormonal disorder of reproductive age and carries a lipid fingerprint of its own: elevated triglycerides, low HDL, and small dense LDL particles, even when total LDL appears normal. ACOG Practice Bulletin on PCOS recognizes the elevated metabolic risk and recommends cardiovascular risk screening in women with PCOS regardless of BMI.

Rosuvastatin is occasionally used in reproductive-age women with familial hypercholesterolemia (FH) or PCOS-related dyslipidemia, but requires concurrent reliable contraception because of its teratogenicity. Evolocumab is generally not a first-line agent in this age group unless FH is confirmed and LDL remains dangerously elevated despite maximally tolerated statin therapy.

Perimenopause (Ages 40 to 52 on Average)

The menopausal transition drives a sharp rise in LDL, often by 10 to 15 mg/dL, independent of dietary changes. Data from the Study of Women's Health Across the Nation (SWAN) documented significant LDL increases tied to the late reproductive and early menopausal transition stages. A woman who was borderline-high at 38 may cross into high-risk territory at 47 purely because of the hormonal shift.

This is the life stage where many women first qualify for statin therapy. Rosuvastatin is typically the right starting point.

Post-Menopause (Ages 52 and Beyond)

Post-menopausal women carry cardiovascular risk profiles that approach those of men in the same age group, and women with established ASCVD (prior MI, stroke, peripheral arterial disease) or heterozygous FH are exactly the population most likely to benefit from adding or switching to evolocumab. The absolute risk reduction from LDL-lowering is larger in this group simply because baseline event risk is higher.

Comparing Efficacy: LDL Reduction Numbers by Situation

The two drugs are rarely a true either/or choice. They sit at different steps of the treatment ladder. Here is how the numbers stack up in practical terms.

Rosuvastatin Dose-Response in Women

| Dose | Expected LDL Reduction | |------|------------------------| | 5 mg | ~40% | | 10 mg | ~45 to 48% | | 20 mg | ~50 to 52% | | 40 mg | ~55 to 63% |

The 5 mg dose deserves more attention in women than it typically gets. Given higher plasma concentrations at equivalent doses, starting at 5 mg and titrating every 4 to 6 weeks is a reasonable strategy for women with lower body weight, Asian ancestry, or prior statin-related muscle complaints.

Evolocumab on Top of Rosuvastatin

When rosuvastatin alone does not get LDL to goal, the options are uptitrating the statin (with diminishing returns above 20 mg), adding ezetimibe (which adds another 15 to 20%), or adding evolocumab. FOURIER data demonstrated a mean LDL of 30 mg/dL in the evolocumab group versus 92 mg/dL at baseline, a level of LDL lowering that no statin alone can reach.

For a woman with heterozygous FH and a baseline LDL of 200 mg/dL on maximum-dose rosuvastatin, adding evolocumab could bring her LDL to approximately 50 to 60 mg/dL, which is within guideline-recommended targets for very high-risk patients.

Side Effects: What Women Experience More

Statin-Related Muscle Symptoms

Myalgia (muscle aches without CK elevation) occurs in roughly 5 to 10% of statin users in clinical trials, but observational data and the Women's Health Initiative suggest rates of patient-reported muscle symptoms may be higher in real-world clinical practice, particularly among older women. A meta-analysis of statin muscle effects found that female sex was an independent predictor of myopathy, particularly at higher doses.

The clinical implication: if you develop muscle pain on rosuvastatin 40 mg, dropping to 20 mg or switching to 10 mg with added ezetimibe often resolves symptoms while preserving most of the LDL reduction.

Statin-Related New-Onset Diabetes

The JUPITER trial reported a 25% increase in physician-reported new-onset diabetes in the rosuvastatin 20 mg group versus placebo. Women with PCOS, pre-diabetes, or excess visceral adiposity carry higher baseline insulin resistance and may be more susceptible to this effect. This does not mean statins are contraindicated in women with metabolic risk, but it does mean glucose monitoring makes sense after starting therapy.

Evolocumab Side Effects in Women

Evolocumab's most common adverse effects are injection-site reactions (4.3% in FOURIER vs 2.9% placebo) and nasopharyngitis. Neurocognitive complaints (memory, concentration) were reported at low rates in FOURIER and did not reach statistical significance, but they are worth tracking. No sex-specific side effect signal unique to women has been clearly established in trial data, though the female subgroup in FOURIER was too small to detect rare sex-specific effects.

Pregnancy, Lactation, and Contraception: Read This Section First If You Might Be Pregnant

Both rosuvastatin and evolocumab are contraindicated during pregnancy.

Statins are classified as FDA Pregnancy Category X (under the older system) because of animal teratogenicity data and the theoretical risk of disrupting fetal cholesterol biosynthesis, which is required for normal neural and adrenal development. The FDA label for rosuvastatin states the drug should be discontinued as soon as pregnancy is recognized. Human data on first-trimester statin exposure do not show a consistent pattern of major malformations, but the risk-benefit calculation does not favor continuation given that atherosclerotic cardiovascular disease does not require treatment during the 9 months of pregnancy.

For evolocumab, the FDA prescribing information notes that data in pregnant women are insufficient to establish a drug-associated risk. Animal reproduction studies showed no adverse developmental outcomes at doses up to 12 times the maximum recommended human dose. PCSK9 inhibitors are not approved in pregnancy, and the standard recommendation is to discontinue before conception if planning a pregnancy.

Practical rules for women of reproductive age:

• Use reliable contraception while taking rosuvastatin. Options include combined oral contraceptives (though these can modestly raise LDL and triglycerides), progestin-only pills, an IUD, or barrier methods.
• If you are trying to conceive, discuss a planned statin washout with your clinician. Rosuvastatin has a half-life of approximately 19 hours, so the drug is largely cleared within a few days, but standard guidance typically recommends stopping at least 1 to 3 months before attempting conception.
• Evolocumab has a half-life of approximately 11 to 17 days. Stopping 2 to 3 months before planned conception allows for adequate clearance.
• Neither drug is recommended during breastfeeding. Rosuvastatin does transfer into breast milk in animal studies. For evolocumab, the molecular size of the antibody suggests limited transfer, but human lactation data are absent. The FDA label language recommends weighing the benefits of breastfeeding against the mother's need for the drug.

If you have familial hypercholesterolemia and your LDL climbs dangerously during pregnancy (which it commonly does, as LDL typically rises 25 to 50% during gestation), consult a maternal-fetal medicine specialist. LDL apheresis is the accepted intervention for FH in pregnancy when risk is extreme.

Who Should Consider Each Drug: A Life-Stage Guide

Rosuvastatin Is Usually Right If You:

• Have an LDL above 130 mg/dL with moderate or high ASCVD risk and no prior events
• Have PCOS with dyslipidemia and require contraception (plan accordingly)
• Are a post-menopausal woman whose LDL rose after menopause and who has not yet tried a statin
• Need a cost-effective, proven, oral therapy you can take once daily
• Have heterozygous FH and are starting lipid therapy for the first time

Evolocumab May Be Right If You:

• Have established ASCVD (prior MI, stroke, or peripheral arterial disease) and your LDL remains above 70 mg/dL on maximum-tolerated statin plus ezetimibe
• Have heterozygous FH with LDL consistently above 100 mg/dL despite maximal oral therapy
• Have homozygous FH (where PCSK9 inhibition may provide only modest benefit depending on LDL receptor function)
• Cannot tolerate any dose of any statin, confirmed after a structured re-challenge, and have high or very high cardiovascular risk
• Are a post-menopausal woman with prior cardiovascular events and persistently elevated LDL despite oral therapy

Situations Where the Choice Is More Complicated

Women with hypothyroidism require careful monitoring with either agent. Hypothyroidism raises LDL independently, and untreated or undertreated thyroid disease is one of the most common reversible causes of high cholesterol in women. Correcting thyroid status before adding or escalating lipid therapy can eliminate the need for a medication change entirely.

Women on hormonal contraception, particularly combined estrogen-progestin pills, may see a modest LDL increase and a more pronounced triglyceride rise depending on the progestin type. This does not usually change the statin choice, but it does affect the lipid panel interpretation.

Switching From Crestor to Repatha: When It Makes Sense

Switching from rosuvastatin to evolocumab outright (rather than adding evolocumab on top) is appropriate in a specific and relatively narrow clinical scenario: you have confirmed statin intolerance after re-challenging with at least two different statins at low doses, your cardiovascular risk is high enough to require pharmacologic LDL lowering, and you have documented this intolerance in your medical record.

The 2022 ACC/AHA guideline update on nonstatin therapies is explicit that ezetimibe should be tried before PCSK9 inhibitors in most patients because of the cost differential. If ezetimibe does not get you to goal, or if you cannot tolerate it, evolocumab is the appropriate next step.

A partial switch, meaning taking rosuvastatin at the highest tolerated dose (even if it is just 5 mg twice weekly) alongside evolocumab, often delivers better LDL reduction than evolocumab alone, because any residual statin upregulates LDL receptors that evolocumab then prevents PCSK9 from degrading.

As Dr. Elena Vasquez, board-certified in cardiovascular medicine and women's health at WomanRx, notes: "The women I see who get the most from evolocumab are almost always post-menopausal with established disease who have tried and failed two or three oral options. Starting a 40-year-old woman with borderline-high LDL directly on a PCSK9 inhibitor skips steps her insurer will almost certainly demand anyway, and that delay costs real time."

The Evidence Gap Disclosure Women Deserve

Women have been underrepresented in major lipid trials for decades. The JUPITER trial was 38% female, which is better than many cardiovascular trials but still leaves room for uncertainty about whether the absolute benefit estimates translate precisely to women across age groups. FOURIER was only 24.5% female, and the female subgroup analyses were not powered for independent statistical conclusions.

What this means practically: the directional signal for both drugs is clear and consistent in female subgroups. The magnitude of benefit, particularly in pre-menopausal women or younger women without established disease, is extrapolated from male-dominant data rather than confirmed in adequately powered female-only analyses. A 2021 meta-analysis of sex differences in PCSK9 inhibitor trials found no significant heterogeneity by sex for the primary MACE endpoints, which is reassuring, but the confidence intervals in the female subgroups were wide.

This should not stop you from taking a drug that is likely to benefit you. It should prompt you and your clinician to revisit the decision annually, adjust targets as evidence evolves, and document symptoms carefully so that real-world women's data continues to accumulate.

Monitoring: What to Track and When

On Rosuvastatin

• Fasting lipid panel at 4 to 12 weeks after starting or changing dose, then annually once stable
• CK level only if you develop muscle pain, not as routine screening
• Fasting glucose or HbA1c at baseline and annually, particularly if you have PCOS, pre-diabetes, or metabolic syndrome
• Hepatic function panel at baseline; routine monitoring is not recommended unless symptoms develop
• If you are perimenopausal and starting estrogen therapy concurrently, recheck lipids 8 to 12 weeks after any hormonal change, as estrogen typically lowers LDL further

On Evolocumab

• Fasting lipid panel 4 to 8 weeks after initiating therapy
• Injection-site assessment; rotate sites between abdomen, thigh, and upper arm
• LDL levels below 20 to 25 mg/dL have been sustained in FOURIER without apparent safety signal at 2.2 years median follow-up, though very long-term data beyond 5 years remain limited
• Neurocognitive symptoms are worth flagging to your clinician, even though the clinical trial signal was not significant